Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into the sequencing of immunotherapies in diffuse large B-cell lymphoma (DLBCL). Prof. Jäger explains that bispecific antibodies are likely to move into the first-line setting for patients with high-risk disease, and further comments on the importance of bispecifics as a treatment option for patients who relapse after CAR-T therapy. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.